165552-33-0

Basic information

• Product Name: 1-ethylpyrrolidine-2-carboxylic acid
• Synonyms: 1-ethylpyrrolidine-2-carboxylic acid;1-ethylproline(SALTDATA: FREE);1-ethyl-2-pyrrolidinecarboxylic acid;1-ethylproline
• CAS NO: 165552-33-0
• Molecular Formula: C7H13NO2
• Molecular Weight: 143.18362
• Mol File: 165552-33-0.mol

Chemical Properties

• Boiling Point: 243.6°C at 760 mmHg
• Flash Point: 101.1°C
• Appearance: /
• Density: 1.104g/cm³
• Vapor Pressure: 0.0105mmHg at 25°C
• Refractive Index: 1.489
• CAS DataBase Reference: 1-ethylpyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ethylpyrrolidine-2-carboxylic acid(165552-33-0)
• EPA Substance Registry System: 1-ethylpyrrolidine-2-carboxylic acid(165552-33-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 165552-33-0(Hazardous Substances Data)

Usage

Class

Proline analogs

Structure

A derivative of the amino acid proline with an ethyl group attached to the nitrogen atom of the pyrrolidine ring

Applications

a. Synthesis of peptides and pharmaceuticals
b. Improving stability and solubility of peptide drugs
c. Potential anti-inflammatory properties
d. Potential neuroprotective properties
e. Development of new therapeutic agents
f. Chiral building block in the production of chiral catalysts and ligands

Industries

Pharmaceutical, chemical, and research

Potential uses

a. Enhancing the properties of existing drugs
b. Developing new drugs with improved efficacy and safety
c. Creating chiral catalysts and ligands for asymmetric synthesis

Research focus

Exploring its anti-inflammatory and neuroprotective properties for therapeutic applications

Chemical properties

a. Amino acid derivative
b. Contains an ethyl group and a carboxylic acid group
c. Part of the proline family, which is known for its unique properties in peptide structures

Safety

As with any chemical, proper handling and storage are necessary to minimize risks. Consult relevant safety data sheets and guidelines for specific precautions.

InChI:InChI=1/C7H13NO2/c1-2-8-5-3-4-6(8)7(9)10/h6H,2-5H2,1H3,(H,9,10)

Upstream product

• 101738-88-9 1-ethyl-pyrrolidine-2,2-dicarboxylic acid diethyl ester 
• 54288-59-4 diethyl 2-bromo-2-(3-bromopropyl)malonate 
• 64-17-5 ethanol 
• 609-36-9 rac-Pro-OH 
• 16652-71-4 benzyl (2S)-2-pyrrolidinecarboxylate hydrochloride 
• 74-96-4 ethyl bromide 
• 147-85-3 L-proline 
• 107599-40-6 N-ethyl-L-proline methyl ester 
• 41324-66-7 H-Pro-OBzl 

Downstream Products

• 938-54-5 N-ethyl ethyl prolinate 
• 3433-34-9 1-ethyl-2-hydroxymethylpyrrolidine 
• 1412974-79-8 (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidin-2-yl)carbonylaminomethyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid 
• 945751-13-3 C₂₇H₃₂N₆O₂ 
• 1412975-05-3 (1aRS,7bSR)-5-(2-{N-[((R)-1-ethylpyrrolidine-2-yl)carbonyl]-N-methylamino-methyl}-4-fluorobenzenesulfonylamino)-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid 

Relevant articles and documents

EPHA4 CYCLIC PEPTIDE ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed herein are compounds and methods of use thereof for the modulation of EphA4 receptor activity. In an aspect, is provided a method of treating or preventing a disease or disorder mediated by EphA4, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein, including certain embodiments, or the structural Formula (I), (l-A), (II), (III), (IV), (IV-1), (V), (Vl-A), (Vl-B), (VII-1), (VII-2), (VIII-1), or (VIII-2), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS

2-Pyrrolidine phenylhydrazides antibacterial agents The present invention relates to 2-pyrrolidine phenylhydrazide compounds of formula (I), which are selective antibacterials specifically agalnstAcineto barter baumannii.The invention also relates to their therapeutic use as antibacterials, to a process for their preparation and to pharmaceutical compositions containing them.

N-ALKYLATED AMINO ACIDS AND OLIGOPEPTIDES, USES THEREOF AND METHODS FOR PROVIDING THEM.

The invention relates to the synthesis of amphiphilic amino acid derivatives, in particular to a method for the N-alkylation of an unprotected amino acid or the N-terminus of an oligopeptide substrate, comprising reacting said unprotected amino acid or oligopeptide substrate with an alcohol, e.g. a fatty alcohol, in the presence of a homogeneous transition metal catalyst.

Modulating hydrogen-bond basicity within the context of protein-ligand binding: A case study with thrombin inhibitors that?reveals a dominating role for desolvation

Understanding subtle aspects of hydrogen bonding is a challenging but crucial task to improve our ability to design ligands with high affinity for protein hosts. To gain a deeper understanding of these aspects, we investigated a series of thrombin inhibitors in which the basicity of the ligand's group that accepts an H-bond from Gly216 was modulated via bioisosterism; e.g., a C=O acceptor was made electron deficient or rich via bioisosteric replacements of the adjacent moiety. Although the ligand's binding affinity was anticipated to improve when the H-bond basicity is increased (due to stronger H-bonding with the protein), we herein present data that unexpectedly revealed an opposite trend. This trend was attributed to a dominating role played by desolvation in determining the relative binding affinity. For example, a decrease in the H-bond basicity reduces the desolvation penalty and, as experimentally observed, improves the binding affinity, given that the reduction in the desolvation penalty dominates the change in the net contribution of the ligand's interactions with the protein. The current study, therefore, reveals that desolvation can be a major underlying cause for the apparently counterintuitive structure-activity relationship (SAR) outcomes, and indicates that understanding this factor can improve our ability to predict binding affinity and to design more potent ligands.

A (S) (-) - amisulpride preparation method

The invention relates to a preparation method of (S)(-)-amisulpride. According to the preparation method, by introducing an R2 group which is selected from benzyl, p-methoxybenzyl, 2,4-dimethoxybenzyl, p-nitrobenzyl and p-methylbenzyl, on one hand, the steric hindrance is increased, the side reaction is avoided, on the other hand, amino is activated, the nucleophilicity of amino is increased, and the condensation reaction can be easily carried out at mild conditions. The preparation method has the characteristics that the raw materials are low in toxicity and easily available, and the reaction conditions are mild; the generation of chiral isomer dextroisomers is avoided; the preparation method is applicable to the industrial production.

METHODS OF TREATING LIVER DISEASES

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.

PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Efficient and chemoselective alkylation of amines/amino acids using alcohols as alkylating reagents under mild conditions

We report a mild and environmentally benign method for the synthesis of tertiary amines using alcohols as the alkylating reagents. Not only secondary amines such as piperazines but also amino acids and amino alcohols can be N-alkylated selectively. For N,O-benzyl protected amino alcohols, both N,O-de-benzylation and N-methylation were achieved in one-pot. The Royal Society of Chemistry.